AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21795500 — intervention group
Group type: COMPARATOR
Intervention: Screening only
Number of subjects: 31
Study 19318632 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, 5-fluorouracil)
Number of subjects: 213
Study 19318632 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin, 5-fluorouracil)
Number of subjects: 213
Study 16525578 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up exercise (WUE)
Number of subjects: 23
Study 16525578 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIE)
Number of subjects: 23
Study 16525578 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity exercise (LIE)
Number of subjects: 23
Study 12598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic facial immersion in 6.0 ± 1.2 degrees C water under -20 mmHg LBNP
Number of subjects: 6
Study 12598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic facial immersion in 6.0 ± 1.2 degrees C water during +40 mmHg LBPP
Number of subjects: 6
Study 12598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic facial immersion in 6.0 ± 1.2 degrees C water during postexercise hypotension (PEH)
Number of subjects: 6
Study 12598488 — intervention group
Group type: COMPARATOR
Intervention: Apneic facial immersion in 6.0 ± 1.2 degrees C water during normal resting (control)
Number of subjects: 6
Study 10766888 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg) with standard Sinemet
Number of subjects: 14
Study 10766888 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg) with Sinemet CR
Number of subjects: 14
Study 10766888 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard Sinemet
Number of subjects: 14
Study 9291769 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 26
Study 9291769 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 26
Study 8142334 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk-free diet during late pregnancy and lactation
Number of subjects: 38
Study 8142334 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (atopic group)
Number of subjects: 38
Study 8142334 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (non-atopic group)
Number of subjects: 38
Study 3163301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (4 gm)
Number of subjects: 152
Study 3163301 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and Metronidazole (5-day cover)
Number of subjects: 152
Study 29650807 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT care coordination (CC) intervention
Number of subjects: 0
Study 29650807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27919251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory awareness training
Number of subjects: 44
Study 27919251 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional motor practice
Number of subjects: 44
Study 27919251 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching only (Control)
Number of subjects: 44
Study 27919251 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip-lift task (Preload Duration for the non-dominant hand)
Number of subjects: 44
Study 27919251 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study 26290103 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/120 kcal whey protein
Number of subjects: 16
Study 26290103 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g/280 kcal whey protein
Number of subjects: 16
Study 26290103 — intervention group
Group type: COMPARATOR
Intervention: Flavored water control drink (0 g whey protein)
Number of subjects: 16
Study 26290103 — intervention group
Group type: COMPARATOR
Intervention: All three drinks (including control)
Number of subjects: 16
Study 26290103 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 16
Study 23287635 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone injection plus oral E2 supplementation (Group A)
Number of subjects: 402
Study 23287635 — intervention group
Group type: COMPARATOR
Intervention: Progesterone injection alone (Group B)
Number of subjects: 402
Study 20568427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with cupping and western medicine (group A)
Number of subjects: 186
Study 20568427 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture combined with cupping (group B)
Number of subjects: 186
Study 20568427 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (group C)
Number of subjects: 186
Study 18223390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 18223390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16987363 — intervention group
Group type: EXPERIMENTAL
Intervention: E120 group (120 mg etoricoxib)
Number of subjects: 75
Study 16987363 — intervention group
Group type: EXPERIMENTAL
Intervention: E + P group (120 mg etoricoxib + 1 g paracetamol)
Number of subjects: 75
Study 16987363 — intervention group
Group type: COMPARATOR
Intervention: Pla group (placebo)
Number of subjects: 75
Study 14501603 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (Premarin, 1.25 mg)
Number of subjects: 60
Study 14501603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11073759 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg every day combined with ethambutol
Number of subjects: 246
Study 11073759 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice a day combined with ethambutol
Number of subjects: 246
Study 9358617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCC)
Number of subjects: 56
Study 9358617 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental product series of PCC
Number of subjects: 56
Study 1286738 — intervention group
Group type: EXPERIMENTAL
Intervention: ViviScal (two tablets once daily for 6 months)
Number of subjects: 20
Study 1286738 — intervention group
Group type: COMPARATOR
Intervention: Fish extract (two tablets once daily for 6 months)
Number of subjects: 20
Study 2844334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet
Number of subjects: 30
Study 28724200 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 30 mg twice daily for 7 days
Number of subjects: 41
Study 28724200 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard TBI management)
Number of subjects: 41
Study 27849461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossur Variflex
Number of subjects: 14
Study 27849461 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolite Elite Blade
Number of subjects: 14
Study 27849461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossur Re‐Flex Rotate
Number of subjects: 14
Study 27849461 — intervention group
Group type: COMPARATOR
Intervention: Control (nonamputee)
Number of subjects: 14
Study 24280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (65%-80% of maximal heart rate, 40-60 min/day, 3-6 days/week for 12 weeks)
Number of subjects: 30
Study 24280041 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 30
Study 23169607 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-031 (3 mg/kg s.c.)
Number of subjects: 48
Study 23169607 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-031
Number of subjects: 48
Study 23169607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21122637 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 4747
Study 21122637 — intervention group
Group type: COMPARATOR
Intervention: ERN-Niaspan (ERN-NSP)
Number of subjects: 4747
Study 21122637 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin or placebo (SIMVA-PBO)
Number of subjects: 4747
Study 18435331 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion removal first (Group 1, 30 eyes)
Number of subjects: 109
Study 18435331 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion removal after another cannula (Group 2, 32 eyes)
Number of subjects: 109
Study 18435331 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion removal last (Group 3, 33 eyes)
Number of subjects: 109
Study 18435331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotony persisted through postoperative day 2 (IOP <= 5 mm Hg)
Number of subjects: 109
Study 16139962 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Intervention (SB)
Number of subjects: 79
Study 16139962 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Intervention (RP)
Number of subjects: 79
Study 12499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 271
Study 12499519 — intervention group
Group type: COMPARATOR
Intervention: Predilatation Stenting (PS)
Number of subjects: 271
Study 10806605 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (Azmacort HFA 225 mcg Inhalation Aerosol)
Number of subjects: 18
Study 10806605 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort Turbuhaler 200 mcg)
Number of subjects: 18
Study 10806605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10806605 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide and Budesonide
Number of subjects: 18
Study 9015909 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 1 x 100 IU/day intramuscularly for 4 weeks
Number of subjects: 41
Study 9015909 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline, 1 ml/day intramuscularly for 4 weeks
Number of subjects: 41
Study 1321181 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized sural nerve grafts
Number of subjects: 49
Study 1321181 — intervention group
Group type: COMPARATOR
Intervention: Conventional sural nerve grafts
Number of subjects: 49
Study 6638669 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (4 doses of 30 g each, administered every 2 hours)
Number of subjects: 7
Study 6638669 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (4 doses of 30 g every 2 hours) in a patient with initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity
Number of subjects: 7
Study 6638669 — intervention group
Group type: COMPARATOR
Intervention: No activated charcoal (control group)
Number of subjects: 7
Study 30268806 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness training intervention (n=28)
Number of subjects: 55
Study 30268806 — intervention group
Group type: COMPARATOR
Intervention: 8-week psychoeducational materials (control group, n=27)
Number of subjects: 55
Study 30143005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine nitrosylation
Number of subjects: 278
Study 30143005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyr-NO2 levels
Number of subjects: 278
Study 30143005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine/Tyr-NO2 ratio
Number of subjects: 278
Study 27527501 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation combined with endurance and resistance training
Number of subjects: 115
Study 27527501 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 115
Study 24530600 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ASP9831
Number of subjects: 96
Study 24530600 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASP9831
Number of subjects: 96
Study 24530600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23094083 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy bar supplementation (4.1 MJ•day(‐1))
Number of subjects: 26
Study 23094083 — intervention group
Group type: COMPARATOR
Intervention: Control group with traditional field rations
Number of subjects: 26
Study 23094083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 20676027 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 24
Study 20676027 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 24
Study 17437506 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (more than 6 bands per session)
Number of subjects: 86
Study 17437506 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (up to 6 bands per session)
Number of subjects: 86
Study 17437506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 86
Study 15866088 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day) plus atorvastatin (20 mg/day)
Number of subjects: 120
Study 15866088 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (5 mg/day)
Number of subjects: 120
Study 12410869 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐Lact (low‐osmolality lactose‐free formula)
Number of subjects: 180
Study 12410869 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐Lac (lactose‐free formula)
Number of subjects: 180
Study 12410869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaré (partially hydrolysed formula)
Number of subjects: 180
Study 12410869 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐Lact (low‐osmolality lactose‐free formula) in malnourished subgroup
Number of subjects: 180
Study 10340182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors treatment initiated and monitored by primary care physicians
Number of subjects: 0
Study 10340182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors treatment
Number of subjects: 0
Study 9118296 — intervention group
Group type: EXPERIMENTAL
Intervention: p55 clonality assay
Number of subjects: 37
Study 9118296 — intervention group
Group type: COMPARATOR
Intervention: G6PD assay
Number of subjects: 37
Study 2192570 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol infusion with analgesia from bolus doses of papaveretum
Number of subjects: 37
Study 2192570 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of papaveretum supplemented by bolus doses of midazolam
Number of subjects: 37
Study 395771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate isomers (4.5 g per day for 64 months)
Number of subjects: 48
Study 395771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin polysulfate (4.5 g per day for 64 months)
Number of subjects: 48
Study 395771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin 4-sulfate and/or chondroitin 6-sulfate (4.5 g per day for 64 months)
Number of subjects: 48
Study 30938691 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (multifaceted Android or iOS app comprising a personalized profile and quit plan, text and in-app motivational messages, and a challenge feature)
Number of subjects: 49
Study 30938691 — intervention group
Group type: COMPARATOR
Intervention: Usual cessation support services (control group)
Number of subjects: 49
Study 30938691 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 49
Study 28950149 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOSS (floss band applied to both ankles)
Number of subjects: 69
Study 28950149 — intervention group
Group type: COMPARATOR
Intervention: CON (without flossing of the ankle joints)
Number of subjects: 69
Study 25952471 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized web-based cardiovascular risk service (CVRS) managed by clinical pharmacists, intervention duration of 12 months.
Number of subjects: 12
Study 25952471 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group), duration of 12 months.
Number of subjects: 12
Study 23968802 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified instructional format designed to reduce cognitive load
Number of subjects: 24
Study 23968802 — intervention group
Group type: COMPARATOR
Intervention: Control instructional format
Number of subjects: 24
Study 21254788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole as adjunctive therapy to antidepressants
Number of subjects: 1090
Study 21254788 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 1090
Study 19450035 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisting tempting sweets
Number of subjects: 101
Study 19450035 — intervention group
Group type: COMPARATOR
Intervention: Resisting less tempting vegetables
Number of subjects: 101
Study 18833207 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial infiltration of the maxillary central incisors
Number of subjects: 60
Study 18833207 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection into incisive papilla (Control)
Number of subjects: 60
Study 16336912 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulated bone mixed with PRP (test)
Number of subjects: 19
Study 16336912 — intervention group
Group type: COMPARATOR
Intervention: Onlay block grafts without additional PRP (control)
Number of subjects: 19
Study 16336912 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulated bone grafts with PRP (test)
Number of subjects: 19
Study 16336912 — intervention group
Group type: COMPARATOR
Intervention: Particulated bone grafts without PRP (control)
Number of subjects: 19
Study 11882746 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 75 mg twice daily
Number of subjects: 51
Study 11882746 — intervention group
Group type: COMPARATOR
Intervention: placebo tablet twice daily
Number of subjects: 51
Study 10225502 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Eye Movement Desensitization and Reprocessing (EMDR) treatment
Number of subjects: 27
Study 10225502 — intervention group
Group type: COMPARATOR
Intervention: Similar treatment without the explicit cognitive elements found in EMDR
Number of subjects: 27
Study 8907208 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (partial ileal bypass)
Number of subjects: 838
Study 2676530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam
Number of subjects: 50
Study 2676530 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and two-stage infusion of propofol in a subanaesthetic dose
Number of subjects: 50
Study 1001000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg to 1200 mg/day in divided doses)
Number of subjects: 427
Study 31697365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored geriatric assessment (GA) summary with recommendations for each enrolled patient
Number of subjects: 541
Study 31697365 — intervention group
Group type: COMPARATOR
Intervention: Usual care (alerts only for patients meeting criteria for depression or cognitive impairment)
Number of subjects: 541
Study 30189371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue group (shuttle-run test to maximal exhaustion)
Number of subjects: 30
Study 30189371 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting in sitting position for 15 minutes)
Number of subjects: 30
Study 30189371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue group
Number of subjects: 30
Study 30189371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group (daily intake of 1080mg EPA + 200mg DHA for 12 weeks)
Number of subjects: 49
Study 29173690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 29173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group
Number of subjects: 49
Study 26367143 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (MUA)
Number of subjects: 30
Study 26367143 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA) with additional subacromial injection of triamcinolone and bupivacain
Number of subjects: 30
Study 23201448 — intervention group
Group type: EXPERIMENTAL
Intervention: FraxiPure™ (1000 mg daily for 90 days)
Number of subjects: 100
Study 23201448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 100
Study 23201448 — intervention group
Group type: EXPERIMENTAL
Intervention: FraxiPure™
Number of subjects: 100
Study 21615691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g and Ketorolac 20 mg combination
Number of subjects: 11
Study 21615691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg
Number of subjects: 11
Study 21615691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 11
Study 21615691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 11
Study 21615691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18292916 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus exercise
Number of subjects: 70
Study 18292916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential electrotherapy plus exercise
Number of subjects: 70
Study 18292916 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 16804739 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter plus offer of a free bone mineral density (BMD) test (n=80)
Number of subjects: 254
Study 16804739 — intervention group
Group type: COMPARATOR
Intervention: Personalized letter only (n=79)
Number of subjects: 254
Study 16804739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (personalized letter and personalized letter plus BMD offer)
Number of subjects: 254
Study 16804739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who contacted their primary care physician
Number of subjects: 254
Study 16804739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants tested for BMD
Number of subjects: 254
Study 12637702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 to 300 mg/d)
Number of subjects: 31
Study 12637702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 31
Study 12637702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Clopidogrel (combined therapy)
Number of subjects: 31
Study 12637702 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 31
Study 10818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine once daily
Number of subjects: 5669